Oral cabazitaxel not checked
Jina Pharmaceuticals Inc. · 50 mg cabazitaxel · 100 mg cabazitaxel
FollowEvery change as it happens, and a Monday email
Trials
3 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Taxane chemotherapy: stops cancer cells from dividing.-taxel: taxane derivatives WHO name stem
- How it’s given
- “200 mg cabazitaxel to be taken every 3-week for 6 cycles (1 dose per cycle), 10 mg prednisone to be taken daily till end of cycle 6”In the company’s words, NCT06890832 on ClinicalTrials.gov
- Main trialPhase 2
- “A total of 75 participants will be enrolled in the study, with 25 participants allocated per intervention group. In Group 1, participant will take 50 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 2, participant will take 100 mg cabazitaxel every week for 6 cycles (3 doses per cycle), 10 mg prednisone daily till the end of cycle 6. In Group 3, participant will take 200 mg cabazitaxel every 3 weeks for 6 cycles (1 doses per cycle), 10 mg prednisone daily till the end of cycle 6. The study comprises three phases: a 21-day…”In the company’s words, NCT06890832 on ClinicalTrials.gov
- Other names
- 50 mg cabazitaxel · 100 mg cabazitaxel · 200 mg cabazitaxel
Other drugs for Metastatic Castration-resistant Prostate Cancer, MCRPC
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone AcetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamideAstellas · Pfizer · Phase 3
- MevrometostatPfizer · Phase 3
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Dec 2026 | A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | |
| Phase 2Ended | not given | A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer | |
| Phase 3Authorised | not given | Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial | |
| Phase 3Authorised | not given | PEACE2 : A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026